Announcement & Notice - Disclosure - Investor Relations

Investor Relations

Effective Communication Drives Development

Corporate Governance Stock Information Disclosure Financials Presentations and Events Analyst Coverage Notices-Replacement of Lost Share Certificates Subscribe to Updates

Home > Investor Relations > Disclosure

Disclosure

Listing Documents Financial Report/ESG information Announcement & Notice IR Journal

2023-04-14

VOLUNTARY ANNOUNCEMENT - RESULTS FROM PHASE IB CLINICAL TRIAL OF PORUSTOBART (HBM4003) IN COMBINATION WITH TORIPALIMAB IN ADVANCED HIGH-GRADE NEUROENDOCRINE NEOPLASMS
2023-04-12

Next Day Disclosure Return
2023-04-04

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2023
2023-03-31

Next Day Disclosure Returns
2023-03-30

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2022
2023-03-17

DATE OF BOARD MEETING
2023-03-06

VOLUNTARY ANNOUNCEMENT - POSITIVE TOPLINE RESULTS FROM PHASE III TRIAL OF BATOCLIMAB (HBM9161) FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS
2023-02-14

INSIDE INFORMATION ENTERING INTO LICENSE AND COLLABORATION AGREEMENT WITH CULLINAN ONCOLOGY, INC. FOR HBM7008
2023-02-07

VOLUNTARY ANNOUNCEMENT - FOOD AND DRUG ADMINISTRATION OF THE UNITED STATES INDCLEARANCE FOR HBM1022 CLINICAL TRIAL INITIATION
2023-01-13

VOLUNTARY ANNOUNCEMENT - FOOD AND DRUG ADMINISTRATION OF THE UNITED STATES IND CLEARANCE FOR HBM1020 CLINICAL TRIAL INITIATION
2023-01-06

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
2022-12-23

INSIDE INFORMATION - FURTHER BUSINESS UPDATE ON COLLABORATION WITH KELUN-BIOTECH IN CONNECTION WITH ANTIBODY-DRUG CONJUGATE
2022-12-23

SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTION DISPOSAL OF ASSETS
2022-12-09

VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE OF COLLABORATION WITH KELUN-BIOTECH
2022-12-08

VOLUNTARY ANNOUNCEMENT - RESULTS FROM PHASE I CLINICAL TRIAL OF PORUSTOBART (HBM4003) IN COMBINATION WITH TORIPALIMAB IN ADVANCED MELANOMA
2022-11-21

VOLUNTARY ANNOUNCEMENT - ENTERING INTO COLLABORATION AGREEMENT WITH DRAGONFLY THERAPEUTICS
2022-11-15

DISCLOSEABLE TRANSACTION - DISPOSAL OF ASSETS
2022-11-11

CHANGE IN CHIEF FINANCIAL OFFICER AND APPOINTMENT OF CHIEF BUSINESS OFFICER
2022-11-11

INSIDE INFORMATION - ENTERING INTO LICENSE AND COLLABORATION AGREEMENT WITH MODERNATX, INC.
2022-11-03

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022

1 ···14 15 ···21